Abstract
The COVID-19 epidemic in Brazil experienced two major country-wide lineage replacements, the first driven by the lineage P.2, formerly classified as variant of interest (VOI) Zeta in late 2020 and the second by the variant of concern (VOC) Gamma in early 2021. To better understand how these SARS-CoV-2 lineage turnovers occurred in Brazil, we analyzed 11,724 high-quality SARS-CoV-2 whole genomes of samples collected in different country regions between September 2020 and April 2021. Our findings indicate that the spatial dispersion of both variants in Brazil was driven by short and long-distance viral transmission. The lineage P.2 harboring Spike mutation E484K probably emerged around late July 2020 in the Rio de Janeiro (RJ) state, which contributed with most (∼50%) inter-state viral disseminations, and only became locally established in most Brazilian states by October 2020. The VOC Gamma probably arose in November 2020 in the Amazonas (AM) state, which was responsible for 60-70% of the inter-state viral dissemination, and the earliest timing of community transmission of this VOC in many Brazilian states was already traced to December 2020. We estimate that variant Gamma was 1.56-3.06 more transmissible than variant P.2 co-circulating in RJ and that the median effective reproductive number (Re) of Gamma in RJ and SP states (Re = 1.59-1.91) was lower than in AM (Re = 3.55). In summary, although the epicenter of the lineage P.2 dissemination in Brazil was the heavily interconnected Southeastern region, it displayed a slower rate of spatial spread than the VOC Gamma originated in the more isolated Northern Brazilian region. Our findings also support that the VOC Gamma was more transmissible than lineage P.2, although the viral Re of the VOC varied according to the geographic context.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support was provided by Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) (PCTI-EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude-REGESAM); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (grant 402457/2020-0); CNPq/Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Ministerio da Saude (MS/FNDCT/SCTIE/Decit) (grant 403276/2020-9); Departamento da Ciencia e Tecnologia (DECIT), Ministerio da Saude; Inova Fiocruz/Fundacao Oswaldo Cruz (Grants VPPCB-007-FIO-18-2-30 and VPPCB-005-FIO-20-2-87), INCT-FCx (465259/2014-6) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) (26/210.196/2020). F.G.N, G.L.W, G.B and M.M.S are supported by the CNPq through their productivity research fellowships (306146/2017-7, 303902/2019-1, 302317/2017-1 and 313403/2018-0, respectively). G.B. is also funded by FAPERJ (Grant number E-26/202.896/2018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from EpiCov Database in GISAID (https://www.gisaid.org/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** List of authors and affiliations (Appendix 1)
Data Availability
All data produced are available online at the EpiCoV database in GISAID (https://www.gisaid.org/)